DuPont Animal Nutrition, a business unit of DuPont Nutrition & Biosciences (DuPont), today announced a partnership with Proteon Pharmaceuticals to bring the emerging bacteriophage technology to poultry producers in selected countries, strengthening DuPont’s gut health solutions for poultry and helping to further mitigate antimicrobial resistance (AMR).
The threat of antimicrobial resistance sparked recent investment into bacteriophage technologies. Modern analytics and omics technologies have enabled screening and identification of bacteriophage candidates for a specific bacterial challenge, with significant feed and food safety implications. This emerging technology is already used in the animal food industry.
DuPont invited Proteon Pharmaceuticals to partner for their compatible work culture, solid scientific approach and leading position amongst their peers in bringing phage technology to market.
Poultry farmers in selected markets are already benefiting from using Proteon’s technology to ensure biosecurity via the waterline and to improve production efficiency.
“Proteon Pharmaceuticals is a pioneer in bacteriophage technology used in animal farming. They have been developing this technology for more than 10 years. It has been tested in Europe and Asia and proven in terms of efficacy and stability,” said Aart Mateboer, business leader, DuPont Animal Nutrition. “This technology fits with our nutribiotic approach. We are pleased to add it to our range of solutions for poultry producers.”
“We strongly believe that our technology might be considered as the future of animal health and nutrition and will help to reduce antibiotic use and antimicrobial resistance,” said Jarosław Dastych, CEO, Proteon Pharmaceuticals. “We are excited to take this next step with DuPont to bring the benefits of bacteriophage technology as a feed additive to poultry producers globally.”
For more information, visit http://www.animalnutrition.dupont.com
